Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KDU692
- Development stage
- Preclinical
- Lead developer
- Novartis
- Modality
- Small Molecules
01
Overview
KDU692 is an investigational small molecule inhibitor of *Plasmodium falciparum* phosphatidylinositol 4-kinase (PfPI4K) [6362]. Developed as part of antimalarial drug discovery efforts, KDU692 targets the lipid kinase PfPI4K, which is essential across multiple stages of the malaria parasite's life cycle. In vitro studies have demonstrated that KDU692 possesses potent, stage-specific activity, particularly against the ookinete stage of *Plasmodium falciparum* development [6362]. This profile makes it a promising candidate for transmission-blocking strategies in malaria control, such as incorporation into insecticide-treated bed nets [6362].
02
Targets
PI4KB (Phosphatidylinositol 4-kinase beta)
Beyond the preview
Go deeper on KDU692.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KDU692.